Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Samsung Biologics Co.,Ltd.
  6. News
  7. Summary
    A207940   KR7207940008

SAMSUNG BIOLOGICS CO.,LTD.

(A207940)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Enzolytics Inc. and Samsung Biologics Co., Ltd. Announce Development and Manufacturing Agreement

10/07/2021 | 08:00am EST

Samsung Biologics and Enzolytics announced the signing of a strategic CDMO partnership agreement. Under the terms of the agreement, Samsung Biologics will provide end-to-end CDMO services from cell line development, clinical drug substance, and drug product manufacturing services to support IND filings for Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibodies for the treatment of HIV and SARS-CoV-2. In addition, there will be continuing discussions for other Monoclonal Antibodies being developed by Enzolytics. The Enzolytics protocol offers the opportunity to implement A.I. analysis and provides a platform for creating multiple fully human Monoclonal Antibodies targeting conserved immutable sites on the virus and offering a cure for these viruses. A stable cell line will be manufactured with support from Samsung Biologics' R&D Center in San Francisco. Its related clinical trial materials will be manufactured at Samsung Biologics headquarters in Incheon, South Korea.


ę S&P Capital IQ 2021
All news about SAMSUNG BIOLOGICS CO.,LTD.
11/24GreenLight Biosciences and Samsung Biologics Announce Collaboration to Build Capacity f..
CI
11/23South Korea’s Indexes Decline on Profit-Taking; Naver, LG Chem Decline over 2%
MT
11/19South Korean Stocks Break Three-Day Losses to Close Higher; Samsung Biologics Jumps 6% ..
MT
11/15Samsung Biologics Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
11/15Samsung's Lee visits U.S ahead of likely $17 billion chip plant decision-media
RE
11/15S.Korea stocks end 1% higher on chip, biopharma boost, U.S. data in focus
RE
11/08South Korea Stocks Decline as Investors Eye US, China Inflation Data; Biopharma Stocks ..
MT
11/08S.Korean stocks end at near 1-month low as biopharma shares slump
RE
11/05Samsung Biologics Eyes Expansion in US, Europe
MT
11/02Private S.Korea firms plan $5.4 billion investment to create vaccine hub
RE
More news
Analyst Recommendations on SAMSUNG BIOLOGICS CO.,LTD.
More recommendations
Financials
Sales 2021 1 549 B 1,30 B 1,30 B
Net income 2021 439 B 0,37 B 0,37 B
Net Debt 2021 319 B 0,27 B 0,27 B
P/E ratio 2021 131x
Yield 2021 -
Capitalization 57 564 B 48 100 M 48 238 M
EV / Sales 2021 37,4x
EV / Sales 2022 32,6x
Nbr of Employees 2 886
Free-Float 25,0%
Chart SAMSUNG BIOLOGICS CO.,LTD.
Duration : Period :
Samsung Biologics Co.,Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAMSUNG BIOLOGICS CO.,LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 870 000,00 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
John Chongbo Rim President, Chief Executive Officer & Director
Tae-Han Kim Chairman
Yong-Ho An Managing Director & Head-Process Technology
Hyung-Woo Moon Head-Compliance Support
Seok-Woo Jung Independent Director
Sector and Competitors